HOXA9 and acute myeloid leukemia: There could be multiple reasons for why our results stand in contrast to those of Hou et al. First, we specifically picked Hoxa9 transduction as a driver that broadly recapitulates AML biology, while Hou et al used fusions that are not known to co-occur with PHF6 in patients.